Repair research
A naturally occurring protein that governs cell migration — the compound TB-500 is derived from.
Thymosin Beta-4 is a protein your body produces, found in high concentration in platelets and wound fluid — which is a strong hint about its role. It is the parent molecule of TB-500, the shorter synthetic fragment more commonly sold. The two are frequently conflated; the distinction is that Thymosin Beta-4 is the full 43-amino-acid protein and TB-500 is the active fragment containing the sequence that does most of the work.
Cells move by building and dismantling an internal scaffold made of actin. Thymosin Beta-4 binds the raw material of that scaffold and holds it in a mobilizable pool, which lets cells reorganize and migrate quickly toward damaged tissue. Repair is largely a logistics problem — getting the right cells to the right place — and this is the logistics protein.
Thymosin Beta-4 binds G-actin monomers 1:1, sequestering them and preventing premature F-actin polymerization, thereby maintaining a mobilizable actin pool for cytoskeletal remodeling. It stimulates endothelial migration and proliferation via VEGF and angiopoietin-1, promoting angiogenesis; shifts macrophage polarization from M1 toward M2, reducing inflammation; promotes keratinocyte and fibroblast migration; and exerts anti-apoptotic effects through PI3K/Akt. It preferentially accumulates at injured and inflamed tissue.
Cell migration effects begin within a day. Visible tissue outcomes — closure, revascularization — appear over roughly three to seven days in the animal literature, and human recovery timelines are longer. This is a support compound layered onto a healing process, not an accelerant that overrides biology.
Every page on this site includes this section. If a source only tells you what something does, you are reading marketing.
Human safety data comes from small early-phase trials and is limited but not concerning. Not FDA- or EMA-approved. It is prohibited in sport under WADA rules, which matters for any competing athlete. The angiogenic mechanism means anyone with an active or historical malignancy should involve their oncologist. Not appropriate during pregnancy or breastfeeding.
Confirm what you are actually buying — full-length Thymosin Beta-4 and the TB-500 fragment are priced and dosed differently and are frequently mislabeled. The certificate of analysis should be unambiguous about which one is in the vial.
Not exactly. TB-500 is the shorter synthetic fragment containing the active actin-binding sequence. They are used similarly and often sold interchangeably, but they are different molecules.
Yes. It is prohibited under WADA rules.
Limited. It reached early-phase human trials for wound healing and cardiac indications without completing a path to approval.
General education only goes so far. If you want help deciding whether this is relevant to your goals, history, and current labs, schedule a consultation with the Bearing team.
Request a Consultation